Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research note published on Wednesday morning,Benzinga reports. They currently have a $100.00 price objective on the biotechnology company’s stock.

A number of other research firms also recently weighed in on ARWR. Weiss Ratings upgraded shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 6th. Royal Bank Of Canada increased their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. The Goldman Sachs Group lifted their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 7th. Morgan Stanley boosted their price objective on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. Finally, Bank of America upped their price objective on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Stock Up 8.0%

NASDAQ ARWR opened at $60.77 on Wednesday. The stock has a 50 day moving average price of $63.10 and a 200-day moving average price of $53.18. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $76.76. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The company has a market capitalization of $8.51 billion, a P/E ratio of 39.72 and a beta of 1.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.38). The business had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The company’s revenue for the quarter was up 10461.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.39) EPS. As a group, equities analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Activity

In related news, CEO Christopher Richard Anzalone sold 13,187 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $66.10, for a total transaction of $871,660.70. Following the completion of the transaction, the chief executive officer directly owned 3,792,739 shares of the company’s stock, valued at approximately $250,700,047.90. The trade was a 0.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Patrick O’brien sold 49,493 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the transaction, the chief operating officer owned 474,908 shares in the company, valued at $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 172,100 shares of company stock worth $11,274,732 over the last 90 days. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Tsfg LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $25,000. First Horizon Corp bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at $32,000. WPG Advisers LLC increased its stake in Arrowhead Pharmaceuticals by 384.8% in the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 431 shares during the period. Hantz Financial Services Inc. increased its stake in Arrowhead Pharmaceuticals by 177.1% in the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 471 shares during the period. Finally, Elyxium Wealth LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $54,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.